Harvoni

(Ledipasvir/sofosbuvir)

Harvoni

Drug updated on 11/10/2023

Dosage FormTablet (oral; ledipasvir/sofosbuvir (90mg/400mg, 45mg/ 200mg)); Pellet (oral: ledipasvir/sofosbuvir (45mg/200mg, 33.75mg/150mg))
Drug ClassMultiple
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.
  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1 infection with decompensated cirrhosis, in combination with ribavirin.
  • For the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin.